| Literature DB >> 32596390 |
Vincenza Cannella1, Roberta Altomare1, Vincenza Leonardi2, Laura Russotto1, Santina Di Bella1, Francesco Mira1, Annalisa Guercio1.
Abstract
OBJECTIVE: Biomaterial research for soft tissue augmentation is an increasing topic in aesthetic medicine. Hyaluronic acid (HA) fillers are widely used for their low invasiveness and easy application to correct aesthetic defects or traumatic injuries. Some complications as acute or chronic inflammation can occur in patients following the injection. Biocompatibility assays are required for medical devices intended for human use, in order to prevent damages or injuries in the host. In this study, nine HA fillers were tested in order to evaluate their cytotoxicity and their effects on L929 cell line, according to the UNI EN ISO 10993 regulation.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32596390 PMCID: PMC7273492 DOI: 10.1155/2020/8676343
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Characteristics of the nine HA fillers used.
| Samples | Description |
|---|---|
| Filler 1 | Stabilized hyaluronic acid 20 mg/ml, nonanimal origin, pH 6–7.5 biphasic |
| Filler 2 | Cross-linked hyaluronic acid 20 mg/ml with lidocaine hydrochloride 3 mg/ml, biphasic |
| Filler 3 | Hyaluronic biorevitalizing gel, medium-chain hyaluronic acid 20 mg/ml in a physiologic buffer, produced from |
| Filler 4 | Hyaluronic acid 20 mg/ml-sodium chloride 16 mg/ml, from bacterial biofermentation, BDDE cross-linking agent, monophasic |
| Filler 5 | Reticulated hyaluronic acid 25 mg/ml with lidocaine hydrochloride 3 mg/ml, animal origin, pH 7.2 |
| Filler 6 | Reticulated hyaluronic acid 24 mg/ml in physiological buffered saline, from biotechnological fermentation, low BDDE content, monophasic |
| Filler 7 | Auto cross-linked hyaluronic acid–sodium chloride 18 mg/ml |
| Filler 8 | Hyaluronic acid 2 mg and cross-linked HA 20 mg-sodium chloride 6.9 mg, nonanimal origin, endotoxin- and BDDE-free |
| Filler 9 | Cross-linked hyaluronic acid 20 mg/ml-lidocaine hydrochloride 3 mg/ml pH 7, biphasic |
Figure 1Effects of HA filler extracts and controls on L929 cells at 24 h, 48 h, and 72 h of exposure. Data express the percentage of cell viability.
Cell count of L929 after 72 h exposure to each HA filler.
| Samples | Cells/ml |
|---|---|
| Filler 1 | 530.00 |
| Filler 2 | 1.355.000 |
| Filler 3 | 1.150.000 |
| Filler 4 | 650.000 |
| Filler 5 | 1.005.000 |
| Filler 6 | 1.555.000 |
| Filler 7 | 900.000 |
| Filler 8 | 1.145.500 |
| Filler 9 | 850.000 |
| RC | 1.050.000 |
Figure 2Morphologic evaluation of L929 cells exposed to different HA filler extracts. Observation conduced at 24 h (first column), 48 h (second column), 72 h (third column), and haematoxylin/eosin staining after 72 h (forth column). Magnification 100x.